New long-lasting treatments for eye diseases
Novel Polymer-antibody Conjugates as Long-acting Therapeutics for Ocular Diseases
['FUNDING_SBIR_1'] · DELGEN BIOSCIENCES INC. · NIH-10760186
This study is looking at new ways to make eye treatments for wet age-related macular degeneration (AMD) last longer, so patients won't have to get injections as often, making it easier and safer for them to manage their condition.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DELGEN BIOSCIENCES INC. (nih funded) |
| Locations | 1 site (Chapel Hill, UNITED STATES) |
| Trial ID | NIH-10760186 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative polymer-antibody conjugates aimed at treating wet age-related macular degeneration (AMD), a leading cause of blindness. The approach seeks to create long-acting formulations of existing anti-VEGF therapies, which currently require frequent injections. By improving drug delivery systems, the research aims to enhance the stability and effectiveness of these treatments, potentially reducing the need for regular administration. Patients may benefit from a more convenient and safer treatment option that could lead to better adherence and outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with wet age-related macular degeneration.
Not a fit: Patients with other forms of macular degeneration or those who do not have AMD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and less burdensome treatment for wet AMD.
How similar studies have performed: Other research has shown promise in developing long-acting biologics, indicating potential success for this novel approach.
Where this research is happening
Chapel Hill, UNITED STATES
- DELGEN BIOSCIENCES INC. — Chapel Hill, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PENG, FEI — DELGEN BIOSCIENCES INC.
- Study coordinator: PENG, FEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.